Sigachi Opens Hyderabad R&D Centre Boosts API Innovation

sigachi-opens-hyderabad-r-and-d-centre-boosts-api-innovation

On June 18, 2025, Sigachi Industries inaugurated a state-of-the-art pharmaceutical R&D centre in Hyderabad, marking a decisive step in Active Pharmaceutical Ingredients (API) research and development. The milestone, titled Sigachi Opens Hyderabad R&D Centre Boosts API Innovation, reflects the company’s commitment to accelerating drug innovation, strengthening global pharma compliance standards, and reducing time-to-market for life-saving medicines, positioning India as a leading force in the global pharma supply chain.

Advancing API Innovation in Hyderabad

Hyderabad has evolved into a life sciences innovation hub, home to India’s top pharmaceutical R&D companies, research institutions, and biotech infrastructure. The launch of the Sigachi R&D centre further enhances the city’s reputation as a global pharmaceutical research powerhouse with objectives including:

  • Faster drug discovery and development using advanced laboratories and high-tech equipment.
  • Integrated research and regulatory frameworks for seamless global approvals.
  • Delivers products aligned with international pharmaceutical quality regulations across the US, Europe, and multiple global markets.

By combining drug research, regulatory documentation, and testing processes under one roof, Sigachi is set to dramatically reduce development timelines while ensuring uncompromised quality.

Key Investments and Research Priorities

Sigachi has invested ₹8.3 crore (approximately $1 million) in this high-tech pharmaceutical R&D facility focusing on:

  • Next-generation API manufacturing for cardiovascular and oncology therapies.
  • Croscarmellose Sodium (CCS) production, scheduled for release within the next 18 months.
  • Advanced drug formulation research involving 3D-printed medicines and co-processed MCC blends for global pharmaceutical markets.

This investment demonstrates Sigachi’s commitment to moving beyond excipients and establishing itself as a leading API manufacturing company in India.

Cutting-Edge Capabilities at the Centre

The new facility integrates advanced capabilities critical to drug discovery and development centers in India, including:

  • Safety and stability testing laboratories meeting global regulatory benchmarks.
  • Regulatory documentation support to ensure rapid approvals in international markets.
  • Predictive data analytics to model drug behavior across production and storage cycles.
  • High-performance quality testing systems ensuring compliance with stringent pharma regulations.

With 15–20 experienced scientists on board, this facility is equipped to handle complex pharmaceutical research projects with precision and efficiency.

CEO’s Vision for the Future

Amit Raj Sinha, CEO and Managing Director of Sigachi, emphasized:

“This centre equips us with the talent, technology, and tools required to deliver innovative pharmaceutical solutions to global markets at unmatched speed and quality.”

His statement underlines the company’s focus on healthcare innovation in Hyderabad and global competitiveness in the pharmaceutical sector.

Impact on Hyderabad’s Real Estate Growth

The R&D centre’s launch is also driving premium residential projects near pharma hubs. Urbanrise Opulence in Nizampet is witnessing rising demand from professionals seeking luxury apartments in Hyderabad close to workplaces, educational institutions, and lifestyle amenities. This reflects how pharma-driven real estate growth in Hyderabad is shaping modern urban living while supporting the city’s pharmaceutical ecosystem expansion.

Balancing Growth with Responsibility

Shortly after the R&D centre inauguration, a dust explosion at Sigachi’s Pashamylaram facility caused casualties and injuries. The company took prompt action by:

  • Announcing ₹1 crore in compensation to support every affected family.
  • Pausing production at the unit for 90 days to ensure safety upgrades.
  • Ramping up manufacturing at Gujarat plants to maintain supply commitments.

This response highlights Sigachi’s responsible operational practices and its focus on employee welfare and safety compliance.

Conclusion

The new Sigachi Hyderabad R&D centre marks a transformative leap in pharmaceutical R&D in Hyderabad. Backed by strategic investments, cutting-edge pharma technologies, and a skilled workforce, the facility strengthens both India’s pharmaceutical research leadership and Hyderabad’s position as a global pharma and real estate innovation hub.

With Urbanrise Opulence and other premium residential projects meeting the growing housing demand from pharma professionals, this development story reflects the synergy between drug research advancements and urban infrastructure growth in Hyderabad.